Timothy Shannon

Timothy M.
Shannon is currently the Chairman at Arvinas Operations, Inc. and the Chairman at Halda Therapeutics LLC.
He is also the Executive Chairman at Halda Therapeutics OpCo, Inc., the Director at Vivace Therapeutics, Inc., the Director at Rallybio LLC, and the Director at Rallybio Holdings LLC.
In addition, he is the General Partner at Canaan Management, Inc., the Member at Canaan Partners IX LLC, the Managing Member at Canaan Partners X LLC, and the Managing Member at Canaan Partners XI LLC.
Dr. Shannon's former positions include being the President, Chief Executive Officer & Director at CuraGen Corp.
from 2007 to 2009, the President, Chief Executive Officer & Director at Aldea Pharmaceuticals, Inc. from 2012 to 2013, and the Chairman at Spyryx Biosciences, Inc. He was also the Chairman at Arvinas, Inc. from 2014 to 2023.
Additionally, he served as a Director at VaxInnate Corp., CytomX Therapeutics Holdings LLC, Celldex Therapeutics, Inc., Novira Therapeutics LLC, and Civitas Therapeutics, Inc. He was an Independent Director at CytomX Therapeutics, Inc. from 2012 to 2017 and an Independent Director at NextCure, Inc. from 2015 to 2020.
He is currently an Independent Director at IDEAYA Biosciences, Inc. and an Independent Director at Rallybio Corp.
from 2018 to 2022.
Dr. Shannon's education includes an undergraduate degree from Amherst College in 1981 and a doctorate degree from The University of Connecticut School of Medicine.